ANA 975

Drug Profile

ANA 975

Alternative Names: ANA-975

Latest Information Update: 21 Feb 2017

Price : $50

At a glance

  • Originator Valeant Pharmaceuticals International
  • Class Antivirals; Nucleosides
  • Mechanism of Action Interferon alpha stimulants; Natural killer cell stimulants; Toll-like receptor 7 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis B; Hepatitis C

Most Recent Events

  • 26 Jul 2007 Discontinued - Phase-I for Hepatitis C treatment in Europe (PO)
  • 26 Jul 2007 Discontinued - Phase-I for Hepatitis C treatment in United Kingdom (PO)
  • 26 Jul 2007 Discontinued - Preclinical for Hepatitis B treatment in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top